Intelligence Feed event · Equity · 2026-08-28

    Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim

    Question

    Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim

    Direct answer

    Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim”, revision 1, evidence through 2026-08-28. https://marketontology.com/market-events/2026-08-28/biohaven-secures-795m-licensing-pact-with-sk-biopharmaceuticals-for-opakalim-d99a68

    EQUITY
    Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
    Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.
    BHVN
    Impact
    69
    AUG 28
    SIG
    85%
    BHVN
    Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
    Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.
    → Up to $795 million in milestone and licensing payments provides non-dilutive capital to fund pipeline clinical trials and extends Biohaven's operational cash runway.
    Impact
    Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.
    Affected
    BHVN
    Transmission
    Up to $795 million in milestone and licensing payments provides non-dilutive capital to fund pipeline clinical trials and extends Biohaven's operational cash runway.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BHVNnon-dilutive licensing capital and pipeline milestone monetizationUp1-4wBiohaven secured an exclusive licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 platform.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month